The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 765K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

22 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
270
Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(ADP-ribose) polymerase-1-related diseases, comprising the same as active ingredientBDB
Digmbio
30
Disulfiram derivatives as ALDH1A1 and MAGL inhibitorsBDB
Batterjee Medical College
53
Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitorsBDB
Pfizer
56
Pyridylamino substituted heterotricyclic compounds, and preparation method and pharmaceutical use thereofBDB
Shanghai Haiyan Pharmaceutical Technology Co.
35
Pyrazolo[1,5-a]pyrazin-4-yl derivativesBDB
Pfizer
243
Piperidine derivatives as inhibitors of ubiquitin specific protease 7BDB
Almac Discovery
15
MU opioid receptor modulatorsBDB
University of California
342
Heterocyclylamines as PI3K inhibitorsBDB
Incyte
149
Heteroaromatic compounds as BTK inhibitorsBDB
Boehringer Ingelheim International
4
Isoxazole derivatives as FXR agonists and methods of use therofBDB
Enanta Pharmaceuticals
239
Heterocyclic compounds as PI3K-γ inhibitorsBDB
Incyte
9
Binding of rasagiline-related inhibitors to human monoamine oxidases: a kinetic and crystallographic analysis.BDB
University of Pavia
18
Inhibitors of protein kinase C. 2. Substituted bisindolylmaleimides with improved potency and selectivity.BDB
Roche Products
5
 
Ring Size effect in the PKC inhibitory activities of perhydroazepine analogs of balanol.BDB
Sphinx Laboratories
3
An ethylenamine inhibitor binds tightly to both wild type and mutant HIV-1 proteases. Structure and energy study.BDB
Academy of Sciences of The Czech Republic
4
In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine.BDB
National Cancer Institute-Bethesda
12
Use of medium-sized cycloalkyl rings to enhance secondary binding: discovery of a new class of human immunodeficiency virus (HIV) protease inhibitors.BDB
Upjohn
5
Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors.BDB
Upjohn
1
L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor.BDB
Merck Research Laboratories
14
L-687,908, a potent hydroxyethylene-containing HIV protease inhibitor.BDB
Merck Research Laboratories
18
Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine.BDB
Japan Energy
8
Understanding binding affinity: a combined isothermal titration calorimetry/molecular dynamics study of the binding of a series of hydrophobically modified benzamidinium chloride inhibitors to trypsin.BDB
University of Groningen